Conolidine’s analgesic consequences stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors within the central nervous program, conolidine modulates alternate molecular targets. A Science Innovations analyze found that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availabi... https://josephf832xaz7.bloggactivo.com/profile